Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.
2026-07-22 15:23
•James Brumley •The Motley Fool
••••••• •••••• Axe Capital view
Steady Dividends: Three Stocks Worth Holding Forever
Reliable dividend payers with growth potential can anchor your portfolio for income and stability.
If you're chasing income that lasts, Pfizer, Coca-Cola, and Brookfield Renewable make a compelling trio. Pfizer stands out on the JSE radar through its growth-linked pharma plays, including a promising obesity drug and oncology assets, supporting its solid 6.9% dividend yield. Coca-Cola offers an unmatched record—a 64-year streak of raising dividends—which reflects a resilient brand with dependable cash flow from everyday consumer purchases. Brookfield Renewable doesn’t trade on the JSE but ties directly to the rand via USD/ZAR exposure due to its U.S. listing; its steady income and dividend growth potential appeal to those seeking green energy themes without Brazil or Europe risk. Watch out: Pfizer’s drug pipeline may face regulatory hiccups, Coca-Cola’s currency risks could pressure rand-based income, and shifting global energy policies might slow Brookfield’s growth. Still, the balance of reliable income with growth upsides feels right for income-focused investors in South Africa’s volatile markets. this is just my opinion and not financial advice
Buy Pfizer for growth and yield, hold Coca-Cola for dependable income, and watch Brookfield Renewable as a satellite for green exposure with steady dividends. Avoid chasing yield in unproven sectors for now.
- PFE
- KO
- USD/ZAR
- Regulatory setbacks for Pfizer's drugs
- Rand volatility impacting foreign income
- Policy shifts in renewable energy subsidies
6/10
The article recommends three dividend stocks suitable for long-term buy-and-hold investors: Pfizer, which is developing new blockbuster drugs and entering the obesity drug market; Coca-Cola, with 64 years of consecutive dividend increases and a resilient business model; and Brookfield Renewable, which offers recurring income from renewable energy assets with 5-9% annual dividend growth targets.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: James Brumley
Categories: Rates, Equities, M&A, Capital Returns, Healthcare, Consumer, Retail
Tickers: PFE, KO, BEPC, LLY, NVO, MRK
Sentiment: Positive - Company is developing multiple new profit centers including oncology pipeline from Seagen acquisition, entering high-growth obesity drug market with monthly-dosed GLP-1 drug, and expects to bring at least eight blockbuster drugs to market by 2030. Offers attractive 6.9% forward dividend yield. Demonstrated exceptional dividend reliability with 64 consecutive years of annual dividend increases. Sells consumer staples with stable demand, benefits from high-margin business model focused on syrup sales rather than bottling, and maintains strong cash flow generation.
Keywords: dividend stocks, buy and hold, income investing, dividend growth, pharmaceutical, renewable energy, consumer staples
Insights:
- PFE: Positive: Company is developing multiple new profit centers including oncology pipeline from Seagen acquisition, entering high-growth obesity drug market with monthly-dosed GLP-1 drug, and expects to bring at least eight blockbuster drugs to market by 2030. Offers attractive 6.9% forward dividend yield.
- KO: Positive: Demonstrated exceptional dividend reliability with 64 consecutive years of annual dividend increases. Sells consumer staples with stable demand, benefits from high-margin business model focused on syrup sales rather than bottling, and maintains strong cash flow generation.
- BEPC: Positive: Offers recurring income from diversified renewable energy portfolio with partnerships from major tech companies (Microsoft, Google). Flexible structure enables strategic acquisitions and partnerships, targets 5-9% annual dividend growth and 12-15% net annual returns, positioned to benefit from growing renewable energy demand.